Crispr Therapeutics is an emerging gene editing company focused on the development of Crispr/Cas9-based therapeutics. The company's proprietary platform specializes in clustered regularly interspaced ...

A Kobe University team was able to edit the DNA of Lactobacillus strains directly without a template from other organisms.

CRISPR-Cas9 ... Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the double strand break can result in insertion or deletion mutations, while repair ...

A Kobe University team was able to edit the DNA of Lactobacillus strains directly without a template from other organisms.

Researchers have developed a novel DNA base editing technology that allows precise genetic changes in Lactobacillus strains ...

A Kobe University team was able to edit the DNA of Lactobacillus strains directly without a template from other organisms.

Base editing to get cell therapies on point While a traditional CRISPR-Cas9 platform cleaves both ... including pre-clinical correction of gene mutations underlying progeria, glycogen storage ...

The field of fruit ripening involves complex interactions among metabolites that are regulated by various genetic factors, ...

Researchers have developed a machine learning model that predicts Cas9 proteins that can be tailored with designer properties for therapeutic use.

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $38.54, denoting a -1.76% change from the preceding trading day. Gene therapy developer CRISPR Therapeutics AG ...

Point mutations are often thought of as the raw material of evolution; these small changes include the substitution of one nucleotide with another (often referred to as a single-nucleotide ...